Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the best affordable biotech stocks to invest in now. In a report released on September 8, Justin Smith from Bernstein reiterated a Sell rating on Genmab A/S (NASDAQ:GMAB) without assigning a price target.

In its financial performance release for the first half of 2025, Genmab A/S (NASDAQ:GMAB) reported $1.640 billion in revenue for the first six months of 2025 compared to $1.382 billion for the same period last year.

Management attributed the increase of $258 million, or 19%, to higher DARZALEX® and Kesimpta® royalties attained under the company’s collaborations with Johnson & Johnson and Novartis Pharma, respectively, along with higher net product sales for EPKINLY.

Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases.

Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia.

While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.